Aisha M. Swaih

Aisha M. Swaih

Auto-generated profile, based on publicly available information

Aisha M. Swaih

AstraZeneca (United Kingdom) 6 Bioscience, Oncology OTD Cambridge, United Kingdom

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2020 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
Daniel MaddisonDaniel Maddison
Daniel Maddison
MAMónica Alfonso-Núñez
Mónica Alfonso-Núñez
ASAisha M. Swaih
Aisha M. Swaih
CBCarlo Breda
Carlo Breda
SCSusanna Campesan
Susanna Campesan
FGFlaviano Giorgini
Flaviano Giorgini
The enzyme kynurenine 3-monooxygenase (KMO) operates at a critical branch-point in the kynurenine pathway (KP), the major route of tryptophan metabolism. As the KP has been implicated in the pathogenesis of several human diseases, KMO and other enzymes that control metabolic flux through the pathway are potential therapeutic targets for these disorders. While KMO is localized to the outer mitochondrial membrane in eukaryotic organisms, no mitochondrial role for KMO has been described. In this study, KMO deficientDrosophila melanogasterwere investigated for mitochondrial phenotypesin vitroandin vivo. We find that a loss of function allele or RNAi knockdown of theDrosophilaKMO ortholog (cinnabar) causes a range of morphological and functional alterations to mitochondria, which are independent of changes to levels of KP metabolites. Notably,cinnabargenetically interacts with the Parkinson’s disease associated genesPink1andparkin, as well as the mitochondrial fission geneDrp1, implicating KMO in mitochondrial dynamics and mitophagy, mechanisms which govern the maintenance of a healthy mitochondrial network. Overexpression of human KMO in mammalian cells finds that KMO plays a role in the post-translational regulation of DRP1. These findings reveal a novel mitochondrial role for KMO, independent from its enzymatic role in the kynurenine pathway.


2 July 2026
Verified
Other
Open access
ASAdriana Savoca
Adriana Savoca
DZDiana Zindel
Diana Zindel
RPRadoslaw Polanski
Radoslaw Polanski
DKDemetrios H. Kostomiris
Demetrios H. Kostomiris
MPMohammad Pirmoradian
Mohammad Pirmoradian
WMWilliam McCoull
William McCoull
Optimization parameters for mass spectrometry analysis for in vivo PK.

2 July 2026
Verified
Other
Open access
ASAdriana Savoca
Adriana Savoca
DZDiana Zindel
Diana Zindel
RPRadoslaw Polanski
Radoslaw Polanski
DKDemetrios H. Kostomiris
Demetrios H. Kostomiris
MPMohammad Pirmoradian
Mohammad Pirmoradian
WMWilliam McCoull
William McCoull
Additional data supporting experimental findings on media stability of compounds 1-4

2 July 2026
Verified
Other
Open access
ASAdriana Savoca
Adriana Savoca
DZDiana Zindel
Diana Zindel
RPRadoslaw Polanski
Radoslaw Polanski
DKDemetrios H. Kostomiris
Demetrios H. Kostomiris
MPMohammad Pirmoradian
Mohammad Pirmoradian
WMWilliam McCoull
William McCoull
List of model parameters estimates for the tumour growth inhibition model

2 July 2026
Verified
Other
Open access
ASAdriana Savoca
Adriana Savoca
DZDiana Zindel
Diana Zindel
RPRadoslaw Polanski
Radoslaw Polanski
DKDemetrios H. Kostomiris
Demetrios H. Kostomiris
MPMohammad Pirmoradian
Mohammad Pirmoradian
WMWilliam McCoull
William McCoull
Degradation rate constant obtained from analysis media concentrations of analysed compounds.